Alibaba
BABA
Tesla
TSLA
Netflix
NFLX
Broadcom
AVGO
NVIDIA
NVDA
US Stock MarketDetailed Quotes
VNDA Vanda Pharmaceuticals
- 4.980
- +0.270+5.73%
Close Mar 11 15:59 ET
- 4.980
- 0.0000.00%
Post 16:05 ET
290.41MMarket Cap-15.09P/E (TTM)
5.000High4.650Low677.68KVolume4.730Open4.710Pre Close3.29MTurnover1.31%Turnover RatioLossP/E (Static)58.32MShares6.75052wk High0.54P/B257.15MFloat Cap3.71052wk Low--Dividend TTM51.64MShs Float33.440Historical High--Div YieldTTM7.43%Amplitude0.450Historical Low4.848Avg Price1Lot Size
Trending Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Vanda Pharmaceuticals Stock Forum
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; F...
Can This Personalized Gene Therapy Revolutionize Rare Disease Treatment? Vanda's Latest Breakthrough
Vanda's Earnings Show 17% Growth Despite Losses: Major Pipeline Expansion Could Triple Revenue
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
Thursday, 13th February at 4:01 pm
Q4 2024 total revenues of $53.2 million, +17% compared to Q4 2023
Q4 2024 Fanapt® net product sales of $26.6 million, +18% compared to Q4 2023
Full year 2024 total revenues of $198.8 million, +3% compared to full year 2023
Full year 2025 revenue expected to grow to $210 to $250 million
Psychiatry portfolio revenue expected to grow to greate...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, ...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY,...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you do...
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
Monday, 3rd February at 7:30 am
• Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular Psoriasis
• Vanda expects to immediately begin preparing BLA and MAA applications for the US and EU
• Anaptys to receive $15 million from Vanda, comprised of a $10 million upfront payme...
No comment yet